EICHOR
● Not Yet Recruiting
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
Condition: Encephalopathy · Radiation Effect · Sponsor: Weill Medical College of Cornell University
About this study
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
This description comes directly from the study's public registry record.
Talk to the study team
Rajiv S Magge, MD · 646-962-2185 · ram9116@med.cornell.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Weill Cornell Medicine | New York, New York, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07125222